--- a
+++ b/clusters/9knumclustersv2/clust_1434.txt
@@ -0,0 +1,43 @@
+Be willing to return to the center for all study-related follow up procedures, including blood collections and completion of imaging studies as required by the protocol
+Patients with inability to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
+Able to return for treatment and follow-up on the specified days
+Patients with inability to return for follow-up visits to assess toxicity to therapy
+Patients with known inability to return for follow-up visits or obtain follow-up studies required to assess for toxicity to therapy will be excluded
+Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
+Patients who are unable to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.
+Ability to attend required study visits and return for adequate follow up, as required by this protocol
+Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
+Patients who are unable to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy; telemedicine visits are acceptable
+Ability to return to Duke University Medical Center for adequate follow-up, as required by this protocol
+Agree to follow protocol required evaluations
+Patients must be able to return to surgical facility for  and/or  day (+/-  days) follow up appointment
+Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to device usage plan, other study procedures, and study restrictions
+Able to return for treatment and follow-up as specified in the protocol
+Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
+Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
+Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
+Patients must be willing to return to the clinic for follow-up visits
+Willing to return to participating medical institutions for follow-up
+Must agree to follow pregnancy precautions as required by protocol.
+Inability to Participate Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.
+Ability to attend required study visits and return for adequate follow up, as required by this protocol
+Agree to return for all follow-up evaluations and procedures specified in the protocol
+Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
+Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
+Willingness to return to University of Maryland Greenebaum Cancer Center (UMGCC) or other participating institutions for treatment and follow-up
+Subjects with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
+Ability to return to Duke University Medical Center for adequate follow-up as required by this protocol
+Ability to provide informed consent, and to return to clinic for adequate follow-up for the period that the protocol requires
+The subject must be willing to return to the study center for vaccinations and study-related follow up procedures including blood and tumor collections and completion of imaging studies as required by the protocol.
+Must agree to follow pregnancy precautions as required by the protocol.
+Inability to return for follow-up visits or obtain follow-up studies required to assess toxicity and response to therapy
+Patients who are unable to return for follow-up visits as required by this study
+RECURRENT/ PROGRESSIVE DIPG (STRATUM ): Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
+NON-PROGRESSED DIPG (STRATUM ): Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
+Agreement to return for the trial required follow-up visits
+Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
+Able to follow instructions
+Unable to return for follow-up visits and tests
+Subjects, who, in the opinion of the clinical Investigator, are able to understand this clinical investigation, cooperate with the investigational procedures and are willing to return for all the required post-treatment follow-up visits
+Return for follow-up visits
+Patients must be willing to return to National Institutes of Health (NIH) for follow-up